Ringing in a new year on Wall Street.
Stocks began 2016 on a horrendous note, getting off to their worst two-week start ever. Thankfully, markets quickly erased losses and continued setting new all-time highs. Hopefully, 2017 will bring more record highs. While no one can claim to have a crystal ball, what’s clear is this: Americans are tired of the sluggish economic recovery, and want to see a real boom-time economy. Whether that comes in 2017 or not can’t be known, but the following stocks look attractive going into the new year. Here are seven of the best stocks to buy for 2017.
Ulta Salon, Cosmetics & Fragrance (ticker: ULTA)
Ulta, the beauty retailer and salon chain, has been routinely underestimated by Wall Street. Quarter after quarter, Ulta beats expectations and investors have no choice but to buy the stock. Over the last five years, ULTA stock is up more than 220 percent. There’s more growth ahead for the retailer, which is in the middle of an aggressive multi-year expansion. In 2014, Ulta announced plans to open 500 new stores over the next five years, implying a 70 percent increase in its store count. Ulta is also growing same-store sales at a double-digit pace, and plans to double its market share in the next few years.
Johnson & Johnson (JNJ)
Johnson & Johnson doesn’t have nearly the growth potential that a stock like ULTA has, but what it does have is something that some investors value even more highly: stability and a nice, fat, steady dividend. Johnson & Johnson has been steadily increasing its dividend for 53 consecutive years now, and pays a dividend yield of 2.7 percent, meaningfully higher than the 2.1 percent yield on the 10-year Treasury note. JNJ investors are buying into an insanely diversified health care company; pharmaceutical sales totaled $31.4 billion in 2015, while its consumer franchise brought in $13.5 billion and medical devices revenue clocked in at $25.1 billion. That’s a diversified dynasty.
iShares NASDAQ Biotechnology Index ETF (IBB)
In 2017, Donald Trump will be sworn in as president. As it turns out, that’s likely a major positive for the health care sector, which underperformed in 2016 as it braced for Hillary Clinton to ascend to the presidency. Clinton had promised to crack down on profiteering in the health care sector, and her tweets on these issues could single-handedly move markets. A fine way to bet on the health care sector as a whole without any of the pesky risks associated with individual companies is the IBB, which holds a portfolio of biotech and pharma companies in the Nasdaq. The day after Trump’s victory, IBB soared 8.9 percent.
Match Group (MTCH)
Do you believe in love? Because nowadays you can actually invest in it. Match Group owns an enviable portfolio of online dating platforms, including Match.com, OkCupid, PlentyOfFish and the go-to app of the millennial, Tinder. Match Group has only been public since late 2015, and got off to a strong first year of trading, with shares gaining more than 30 percent in 2016. Judging by MTCH’s third-quarter earnings report, business continues to be booming. Dating revenue was 22 percent higher than it was in the same quarter last year, and the number of paid members grew by 33 percent. In 2017, international growth should be the stock’s core driver.
Facebook (FB)
Facebook is one of the most ubiquitous digital presences on the entire internet, boasting about 1.8 billion monthly active users. That user count was up 16 percent from the same period last year, a remarkable growth rate given the impressive size. Far more remarkable than that, however, is Facebook’s revenue and earnings growth. Revenue soared 56 percent in the third quarter, while earnings per share jumped 165 percent. You can’t expect earnings growth like this forever, especially as Facebook pours more money back into its business, but you can expect Facebook to remain dominant for years to come.
Prudential Financial (PRU)
Prudential is the second-largest American life insurance company by market cap, trailing only MetLife (MET) in size. While Prudential might not be the sexiest-sounding investment, it’s a well-positioned, conservative investment for 2017. Not only does PRU stock trade for less than 10 times forward earnings, it pays a 2.8 percent dividend. And Prudential, like all large insurers, stands to benefit in a rising interest rate environment as it can earn higher interest on the premiums it stows away. Judging by the surge in bond yields after the 2016 election, markets seem to think Trump could bring interest rates higher.
3M (MMM)
Like Johnson & Johnson, 3M is a diversified global commercial powerhouse. It doesn’t make pharmaceuticals, of course, but MMM is similar to JNJ because it’s a fairly conservative stock that can anchor your portfolio and provide regular interest income. Its 2.6 percent dividend yield is nothing to scoff at, and in each of the last 57 years 3M has increased its dividend payout. Sustainable dividends are hard to come by, and so too are large companies with the innovative drive that 3M has; in 2017 3M aims to generate 40 percent of all revenue from products it invented in the last five years.
More from U.S. News
10 Ways to Invest in Pharmaceuticals With ETFs
8 Stocks to Buy For a Starter Portfolio
8 of the Most Incredible Investments of the 21st Century
7 of the Best Stocks to Buy for 2017 originally appeared on usnews.com
